Wed May 28 13:50:00 UTC 2025: Okay, here’s a summary and a rewritten news article based on the provided text:

**Summary:**

Tempus AI, a precision medicine company specializing in artificial intelligence, is expected to perform well due to its acquisition of Ambry Genetics. The first quarterly results post-acquisition have been positive, boosting the stock. An analyst from Stone Fox Capital believes the company is positioned for growth and recommends investors consider undervalued stocks. The analyst also discloses that they do not own shares in the mentioned companies.

**News Article:**

**Tempus AI Stock Jumps After Strong First Quarter Following Ambry Genetics Acquisition**

**NEW YORK, NY** – Shares of Tempus AI, Inc. (NASDAQ:TEM) are on the rise following the release of its first quarterly results since acquiring Ambry Genetics. The AI-powered precision medicine company is experiencing a positive boost from the acquisition, bolstering its outlook for the remainder of the year and beyond.

According to Stone Fox Capital, the acquisition positions Tempus AI for significant growth, making it an attractive investment opportunity. The firm’s analyst highlights the potential for investors to capitalize on undervalued stocks within the current market.

The analyst provides stock picks and deep research to help readers uncover potential multibaggers while managing portfolio risk via diversification. Features include various model portfolios, stock picks with identifiable catalysts, daily updates, real-time alerts, and access to community chat and direct chat with Mark for questions.

*Disclaimer: The analyst from Stone Fox Capital has no stock, option, or similar derivative position in Tempus AI or Ambry Genetics. This article is for informational purposes only and does not constitute investment advice. Investors are encouraged to conduct their own research and consult with a financial advisor before making any investment decisions.*

Read More